Janux Therapeutics (JANX) Return on Capital Employed (2021 - 2026)
Janux Therapeutics (JANX) posted quarterly Return on Capital Employed of 16.42% for Q1 2026, down 549.0% year-over-year from 3.66% in Q1 2025, and down 2.92% quarter-over-quarter from 15.96% in Q4 2025.
Janux Therapeutics (JANX) Return on Capital Employed (2021 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Return on Capital Employed for 6 consecutive years, with 16.42% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 549.0% year-over-year to 16.42%; the TTM figure through Mar 2026 stood at 16.42% (down 549.0% YoY), while the FY2025 annual figure was 15.66%, down 161.0% from the prior year.
- Return on Capital Employed retreated to 16.42% in Q1 2026 per JANX's latest filing, from 15.96% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 9.72% in Q2 2024 and bottomed at 23.48% in Q2 2023.
- Historically, Return on Capital Employed has averaged 15.85% across 5 years, with a median of 15.16% in 2022.
- Annual changes were most pronounced in 2022 — Return on Capital Employed plunged 1158 bps — and 2024, when it surged 1376 bps.
- Janux Therapeutics' Return on Capital Employed stood at 18.99% in 2022, then dropped by 4 bps to 19.69% in 2023, then surged by 42 bps to 11.48% in 2024, then sank by 39 bps to 15.96% in 2025, then retreated by 3 bps to 16.42% in 2026.
- Business Quant data shows JANX's Return on Capital Employed at 16.42% in Q1 2026, 15.96% in Q4 2025, and 14.42% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - | -14.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.99% |
| Mar 31, 2026 | -16.42% |
| Dec 31, 2025 | -15.96% |
| Sep 30, 2025 | -14.42% |
| Jun 30, 2025 | -14.20% |
| Mar 31, 2025 | -10.94% |
| Dec 31, 2024 | -11.48% |
| Sep 30, 2024 | -12.72% |
| Jun 30, 2024 | -9.72% |
| Mar 31, 2024 | -13.90% |
| Dec 31, 2023 | -19.69% |
| Sep 30, 2023 | -21.48% |
| Jun 30, 2023 | -23.48% |
| Mar 31, 2023 | -21.56% |
| Dec 31, 2022 | -18.99% |
| Sep 30, 2022 | -17.11% |
| Jun 30, 2022 | -15.16% |
| Mar 31, 2022 | -12.22% |
| Dec 31, 2021 | -8.84% |
| Sep 30, 2021 | -5.53% |